Boundless Bio
Boundless Bio is a clinical stage precision oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA) to treat oncogene amplified cancers.
Company Overview
Boundless Bio is a clinical stage, next-generation precision oncology company headquartered at 9880 Campus Point Dr, Suite 120, San Diego, CA 92121. The company focuses on addressing oncogene amplifications, a condition present in over 25% of all cancers. By targeting extrachromosomal DNA (ecDNA), Boundless Bio aims to tackle one of the root causes of oncogene amplifications found in more than 5 million newly diagnosed cancers each year.
Pipeline of ecDNA-Directed Therapies
Boundless Bio is advancing a robust pipeline of ecDNA-directed therapies (ecDTx) to treat oncogene amplified cancers. Their leading candidate, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) and is currently in a Phase 1/2 clinical trial called POTENTIATE. Additionally, BBI-825, another ecDTx, is an oral, selective inhibitor of ribonucleotide reductase (RNR) being studied in a first-in-human Phase 1/2 clinical trial named STARMAP. Boundless Bio has also identified a second CHK1 inhibitor candidate, BBI-098, which shows potential for treating CNS cancers.
Technology Platforms
Boundless Bio employs advanced technology platforms to target oncogene amplifications. The company's Spyglass platform identifies vulnerabilities of ecDNA in cancer cells. Additionally, their proprietary ECHO software algorithm detects the presence of ecDNA using routine clinical next-generation sequencing (NGS) data. These technologies enable comprehensive identification and targeting of ecDNA, paving the way for novel cancer therapies.
Current Clinical Trials
Boundless Bio is actively involved in several clinical trials to evaluate the efficacy and safety of their ecDNA-directed therapies. BBI-355 is undergoing a Phase 1/2 clinical trial called POTENTIATE to assess its effectiveness as a CHK1 inhibitor. Concurrently, BBI-825 is being studied in the STARMAP Phase 1/2 trial as a ribonucleotide reductase (RNR) inhibitor. Both trials are first-in-human studies, reflecting Boundless Bio's commitment to delivering transformative therapies for cancer patients.
Mission and Vision
Boundless Bio's mission is to deliver transformative therapies to patients with intractable oncogene amplified cancers. The company's vision is centered around providing powerful anti-cancer therapies that improve and extend the lives of patients affected by ecDNA-driven cancers. As the first company dedicated to treating oncogene amplified cancers, Boundless Bio aims to make significant advancements in precision oncology.